Lappoxo (Omeprazole)

Omeprazole acts on the gastric acid‑secretion pathway and is indicated for several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease (PUD): supports ulcer healing and reduces recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion.
• Helicobacter pylori eradication regimens: used as adjunct‑therapy in combination regimens.
• NSAID‑associated ulcer prophylaxis: lowers risk of ulcer development in chronic NSAID users.

• Omeprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) on the parietal cell surface, blocking the final step of acid secretion. This results in a sustained reduction of gastric acidity, allowing mucosal healing and symptom relief.

Adverse reactions to omeprazole are generally mild to moderate and vary by individual.

Common Side Effects

• Headache: mild, transient headache.
• Diarrhea: loose stools, often self‑limiting.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased gas formation.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis risk.
• Acute interstitial nephritis: kidney inflammation.
• Hypomagnesemia: low magnesium levels with prolonged use.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Liver enzyme elevation: increased ALT/AST.
• Fracture risk: potential decrease in bone density with long‑term therapy.

When using Lappoxo, consider the following safety measures:

• Assess renal function: adjust use in patients with severe kidney impairment.
• Monitor magnesium levels: check periodically during long‑term therapy.
• Evaluate bone health: consider calcium/vitamin D supplementation for prolonged use.
• Review drug history: avoid concurrent use with drugs that require acidic pH for absorption.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Omeprazole may interact with several medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect.
• Atazanavir: decreased antiviral absorption.
• Dasatinib: lowered plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: potential INR fluctuation.
• Phenytoin: altered serum levels.
• Methotrexate: increased toxicity risk.
• Digoxin: enhanced absorption.
• Ketoconazole: reduced antifungal efficacy.